Released Nov 5, 2019, after the close
10-Q filed Nov 5, 2019, 36 days after period end · 0001564590-19-040360
Q3 2019 · 10-Q
Revenue$2.43M$2.43M +136.7% vs Q3 2018−13.8% vs Q2 2019
Net Income-$26.61M-$26.61M N/M vs Q3 2018N/M vs Q2 2019
EPS Diluted-$0.40-$0.40 N/M vs Q3 2018N/M vs Q2 2019
Operating Income-$27,119,000N/M
Operating Cash Flowderived-$19,838,000N/M
Free Cash Flowderived-$21,102,000N/M
Margins · derived
Operating margin-1116.5%+510.4 pt vs Q3 2018
Net margin-1095.5%+540.2 pt vs Q3 2018
What the release said
The release
Same quarter
| Metric | Q3 2019 | Q3 2018 | Q3 2017 | Q3 2016 |
|---|---|---|---|---|
| Revenue | $2.43M | $1.03M | $1.03M | $1.03M |
| Net Income | -$26.61M | -$16.78M | -$10.68M | -$8.74M |
| EPS Diluted | -$0.40 | -$0.31 | -$0.26 | -$0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR